Peyronie's Disease Flashcards
Which of the following statements is true about the non-surgical management of Peyronie’s Disease (PD)?
A. PD affects only men in their later years.
B. PD has a clearly defined management pathway.
C. Deformity less than 30 degrees usually impairs function.
D. PD is a symptom complex that can affect quality of life.
Answer: D
Peyronie’s Disease (PD) is not solely age-dependent and can affect men at different ages. Its management isn’t always straightforward, and deformity less than 30 degrees usually does not impair function. Thus, PD mainly affects the quality of life of those who suffer from it.
Which of the following oral agents is approved for the standard care of PD in Canada?
A. Vitamin E
B. Tamoxifen
C. Procarbazine
D. None of the above
Answer: D
No oral agents are approved for the standard care of PD in Canada. Both vitamin E and Tamoxifen have been tried, but neither has shown consistent efficacy in clinical trials.
What level of evidence supports the use of PDE-5 inhibitors like tadalafil for modifying Peyronie’s plaque progression?
A. Level 1
B. Level 2
C. Level 3
D. Limited to a single published study
Answer: D
The evidence supporting the use of PDE-5 inhibitors for modifying plaque progression in PD is limited to a single published study.
What is the CUA’s position on the use of iontophoresis in PD?
A. Strongly recommended
B. Recommended
C. Not recommended
D. Conditional recommendation
Answer: C
The CUA does not recommend iontophoresis for the treatment of PD, given the lack of convincing evidence.
In terms of intralesional therapies, what is considered as first-line therapy according to the CUA?
A. Verapamil
B. Interferon
C. Collagenase (Xiaflex)
D. Vitamin E
Answer: C
Collagenase (Xiaflex) is considered the first-line intralesional therapy, according to CUA guidelines.
What is the Grade of recommendation for using clostridial collagenase in the management of PD in Canada?
A. Grade A
B. Grade B
C. Grade C
D. Grade D
Answer: B
The grade of recommendation for using clostridial collagenase in the management of PD in Canada is Grade B.
For which of the following deformities has the use of intralesional collagenase not been evaluated?
A. Curvature greater than 90°
B. Isolated hourglass deformity
C. Curvature less than 30°
D. All of the above
Answer: D
The use of intralesional collagenase has not been evaluated for curvature greater than 90°, isolated hourglass deformity, or curvature less than 30°.
What is a common side effect of intralesional verapamil (ILV)?
A. Penile bruising
B. Myocardial infarction
C. Systemic toxicity
D. Renal failure
Answer: A
A common side effect of intralesional verapamil is penile bruising, not myocardial infarction or systemic toxicity.
Which topical therapy has uncertain and only potential efficacy for PD according to the CUA?
A. Iontophoresis with verapamil
B. Dexamethasone gel
C. Verapamil gel
D. Topical Vitamin E
Answer: C
The CUA indicates that the efficacy of verapamil gel in the treatment of PD is uncertain.
Which of the following factors can be a predictor of efficacy in ILV treatment for PD?
A. Older age
B. Smaller baseline curvature
C. Higher dilutions of verapamil
D. Larger plaques
Answer: B
Smaller baseline curvature can be a predictor of efficacy in intralesional verapamil treatment for PD.
What type of agents does clostridial collagenase belong to?
A. Prostaglandins
B. Collagenases
C. Calcium-channel blockers
D. PDE-5 inhibitors
Answer: B
Clostridial collagenase belongs to the group of collagenases.
What is a significant limitation to the evidence for using oral agents in PD?
A. Lack of long-term follow-up studies
B. Heterogeneity of treatments and duration of follow-up
C. Small sample size
D. All of the above
Answer: D
All the options (Lack of long-term follow-up studies, Heterogeneity of treatments, and Small sample size) represent limitations to the evidence for using oral agents in PD.
How does the CUA recommend managing pain in the active phase of PD?
A. Oral non-steroidal anti-inflammatory medication
B. Opioid analgesics
C. Aspirin
D. No recommendation exists
Answer: D
The CUA guidelines do not provide a specific recommendation for managing pain in the active phase of PD.
According to the CUA, at what point should a patient seek treatment for PD based on deformity?
A. Only if deformity is more than 60 degrees
B. Only if deformity is more than 30 degrees
C. There is no minimum criteria for deformity necessary for management
D. Deformity less than 30 degrees is a contraindication for treatment
Answer: C
The CUA guidelines do not specify a minimum degree of deformity for a patient to seek treatment for PD.
What level of evidence and grade of recommendation does the use of iontophoresis have, according to the CUA?
A. Level 2 evidence, Grade A recommendation
B. Level 3 evidence, Grade C recommendation
C. Level 4 evidence, Grade 3 recommendation
D. Level 1 evidence, Grade D recommendation
Answer: B
The use of iontophoresis in PD has Level 3 evidence and receives a Grade C recommendation, according to the CUA.
What is the consensus of the panel regarding the use of oral agents like potassium para-aminobenzoate (POTABA)?
A. The panel favors it as first-line treatment.
B. There is no consensus among the panel.
C. The panel recommends it with reservations.
D. The panel does not recommend it.
Answer: D
The panel does not recommend the use of potassium para-aminobenzoate (POTABA) as a treatment for PD.
What is the age range where congenital penile curvature is typically diagnosed?
A. Adolescence
B. Early childhood
C. Middle age
D. Older age
Answer: A
Congenital penile curvature is typically diagnosed during adolescence.